Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Even with guideline-directed antiplatelet therapy, stroke recurrence rates remain stubbornly high at 5–8%. At a clinical forum in Orlando, neurologists debated DAPT duration, CYP2C19 genotyping, and the newly FDA-approved factor XIa inhibitor asundexian, which cut recurrent ischemic stroke risk by 26% without increasing major bleeding in the landmark OCEANIC-STROKE trial.
Despite following guideline-directed antiplatelet therapy to the letter, stroke recurrence rates still hover between 5% and 8% — a frustrating reality that took center stage at an HCPLive/NeurologyLive Clinical Forum in Orlando. Vascular neurologist David Z. Rose, MD, of USF Morsani College of Medicine, led a candid discussion on why cycling through aspirin, clopidogrel, and related agents without addressing the underlying mechanism continues to fall short of meaningful risk reduction.
A key concern raised was "practice drift" — discharge orders for dual antiplatelet therapy (DAPT) that lack stop dates, leading primary care physicians to simply keep refilling them. Guidelines recommend DAPT for just 21 days after minor stroke or high-risk TIA, and 90 days for intracranial atherosclerosis. Attendees also backed inpatient CYP2C19 genotyping to identify clopidogrel non-responders and switch them to ticagrelor. For recurrent strokes, Rose urged a full vascular and cardiac workup before escalating therapy, and championed implantable loop recorders for cryptogenic stroke patients.
The forum's biggest headline: asundexian (Sunharbo), a factor XIa inhibitor, received FDA approval on November 9, 2026 — less than a month after the forum — for secondary stroke prevention when added to antiplatelet therapy.
By the Numbers:
Why it matters: With asundexian now FDA-approved, clinicians have a new tool to reduce stroke recurrence without adding bleeding risk — but experts caution it must be added to antiplatelet therapy, not substituted for it. Pricing, access, and patient adherence will be critical factors in real-world uptake.